DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.
Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...
In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...
PCMag Australia on MSN
I Tracked My Blood Sugar With a Dexcom Stelo for a Month. Here's What I Learned
The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult ...
One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering gross margin profile is poised to witness an inflection point this year. As you ...
Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...
At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.
People don't buy consumer wearables just to count steps anymore. They want early warnings, useful health signals, and features they can trust.
Opportunities include integrating digital health for remote care, leveraging demographic trends, and overcoming CGM unit costs to expand access across regionsDublin, March 16, 2026 (GLOBE NEWSWIRE) -- ...
Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths - Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warni ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results